Xanthomonas maltophilia endophthalmitis following penetrating corneal injury.
D000666:Amphotericin B / Q000627:therapeutic use; D003315:Cornea / Q000382:microbiology; D065306:Corneal Injuries; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D009877:Endophthalmitis / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D015818:Eye Infections, Bacterial / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D015807:Eye Injuries, Penetrating / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D015725:Fluconazole / Q000627:therapeutic use; D016905:Gram-Negative Bacterial Infections / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000627:therapeutic use; D020615:Stenotrophomonas maltophilia / Q000302:isolation & purification*; D014792:Visual Acuity
D000666:Amphotericin B; D015725:Fluconazole; D015242:Ofloxacin